OBJECTIVES: To assess the impact of variation in prehospital care across distinct health care environments in ASSENT (assessment of the safety and efficacy of a new thrombolytic) -3 PLUS, a large (n = 1639) contemporary multicentred international trial of prehospital fibrinolysis. Specifically, the objectives were to assess predictors of time to treatment, whether components of time to treatment vary across countries, and the impact of physician presence before hospitalisation on time to treatment, adherence to protocol, and clinical events. METHODS: Patient characteristics associated with early treatment (< or = 2 hours), comparison of international variation in time to treatment, and components of delay were assessed. Trial specific patient data were linked with site specific survey responses. RESULTS: Younger age, slower heart rate, lower systolic blood pressure, and prior percutaneous coronary intervention were associated with early treatment. Country of origin accounted for the largest proportion of variation in time. Intercountry heterogeneity was shown in components of elapsed time to treatment. Physicians in the prehospital setting enrolled 63.8% of patients. The presence of a physician was associated with greater adherence to protocol mandated treatments and procedures but with delay in time to treatment (120 v 108 minutes, p < 0.001). CONCLUSION: Country of enrollment accounted for the largest proportion of variation in time to treatment and intercountry heterogeneity modulated components of delay. The effectiveness and safety of prehospital fibrinolysis was not influenced by the presence of a physician. These data, acquired in diverse health care environments, provide new understanding into the components of prehospital treatment delay and the opportunities to further reduce time to fibrinolysis for patients with ST elevation myocardial infarction.
RCT Entities:
OBJECTIVES: To assess the impact of variation in prehospital care across distinct health care environments in ASSENT (assessment of the safety and efficacy of a new thrombolytic) -3 PLUS, a large (n = 1639) contemporary multicentred international trial of prehospital fibrinolysis. Specifically, the objectives were to assess predictors of time to treatment, whether components of time to treatment vary across countries, and the impact of physician presence before hospitalisation on time to treatment, adherence to protocol, and clinical events. METHODS:Patient characteristics associated with early treatment (< or = 2 hours), comparison of international variation in time to treatment, and components of delay were assessed. Trial specific patient data were linked with site specific survey responses. RESULTS: Younger age, slower heart rate, lower systolic blood pressure, and prior percutaneous coronary intervention were associated with early treatment. Country of origin accounted for the largest proportion of variation in time. Intercountry heterogeneity was shown in components of elapsed time to treatment. Physicians in the prehospital setting enrolled 63.8% of patients. The presence of a physician was associated with greater adherence to protocol mandated treatments and procedures but with delay in time to treatment (120 v 108 minutes, p < 0.001). CONCLUSION: Country of enrollment accounted for the largest proportion of variation in time to treatment and intercountry heterogeneity modulated components of delay. The effectiveness and safety of prehospital fibrinolysis was not influenced by the presence of a physician. These data, acquired in diverse health care environments, provide new understanding into the components of prehospital treatment delay and the opportunities to further reduce time to fibrinolysis for patients with ST elevation myocardial infarction.
Authors: Robert J Goldberg; Philippe Gabriel Steg; Immad Sadiq; Christopher B Granger; Elizabeth A Jackson; Andrzej Budaj; David Brieger; Alvaro Avezum; Shaun Goodman Journal: Am J Cardiol Date: 2002-04-01 Impact factor: 2.778
Authors: F Van De Werf; J Adgey; D Ardissino; P W Armstrong; P Aylward; G Barbash; A Betriu; A S Binbrek; R Califf; R Diaz; R Fanebust; K Fox; C Granger; J Heikkilä; S Husted; P Jansky; A Langer; E Lupi; A Maseri; J Meyer; J Mlczoch; D Mocceti; D Myburgh; A Oto; E Paolasso; K Pehrsson; R Seabra-Gomes; L Soares-Piegas; D Sùgrue; M Tendera; E Topol; P Toutouzas; A Vahanian; F Verheugt; L Wallentin; H White Journal: Lancet Date: 1999-08-28 Impact factor: 79.321
Authors: W J Rogers; J G Canto; C T Lambrew; A J Tiefenbrunn; B Kinkaid; D A Shoultz; P D Frederick; N Every Journal: J Am Coll Cardiol Date: 2000-12 Impact factor: 24.094
Authors: Eric Bonnefoy; Frédéric Lapostolle; Alain Leizorovicz; Gabriel Steg; Eugène P McFadden; Pierre Yves Dubien; Simon Cattan; Eric Boullenger; Jacques Machecourt; Jean-Micel Lacroute; Jean Cassagnes; François Dissait; Paul Touboul Journal: Lancet Date: 2002-09-14 Impact factor: 79.321
Authors: David A Morrow; Elliott M Antman; Assaad Sayah; Kristin C Schuhwerk; Robert P Giugliano; James A deLemos; Michael Waller; Sidney A Cohen; Donald G Rosenberg; Sally S Cutler; Carolyn H McCabe; Ron M Walls; Eugene Braunwald Journal: J Am Coll Cardiol Date: 2002-07-03 Impact factor: 24.094
Authors: P G Steg; J-P Cambou; P Goldstein; E Durand; P Sauval; Z Kadri; D Blanchard; J-M Lablanche; P Guéret; Y Cottin; J-M Juliard; G Hanania; L Vaur; N Danchin Journal: Heart Date: 2006-08-16 Impact factor: 5.994
Authors: Iqbal Bata; Paul W Armstrong; Cynthia M Westerhout; Andrew Travers; Sunil Sookram; Edward Caine; James Christenson; Robert C Welsh Journal: Can J Cardiol Date: 2009-08 Impact factor: 5.223
Authors: Jacek Kubica; Piotr Adamski; Jerzy R Ładny; Jarosław Kaźmierczak; Tomasz Fabiszak; Krzysztof J Filipiak; Robert Gajda; Mariusz Gąsior; Zbigniew Gąsior; Robert Gil; Jarosław Gorący; Stefan Grajek; Leszek Gromadziński; Marcin Gruchała; Grzegorz Grześk; Piotr Hoffman; Miłosz J Jaguszewski; Marianna Janion; Piotr Jankowski; Zbigniew Kalarus; Jarosław D Kasprzak; Andrzej Kleinrok; Wacław Kochman; Aldona Kubica; Wiktor Kuliczkowski; Jacek Legutko; Maciej Lesiak; Klaudiusz Nadolny; Eliano P Navarese; Piotr Niezgoda; Małgorzata Ostrowska; Przemysław Paciorek; Jolanta Siller-Matula; Łukasz Szarpak; Dariusz Timler; Adam Witkowski; Wojciech Wojakowski; Andrzej Wysokiński; Marzenna Zielińska Journal: Cardiol J Date: 2022-05-06 Impact factor: 3.487
Authors: Martin Stockburger; Birga Maier; Georg Fröhlich; Wolfgang Rutsch; Steffen Behrens; Ralph Schoeller; Heinz Theres; Stefan Poloczek; Gerd Plock; Helmut Schühlen Journal: Dtsch Arztebl Int Date: 2016-07-25 Impact factor: 5.594
Authors: Wenchi Guan; Arjun K Venkatesh; Xueke Bai; Si Xuan; Jing Li; Xi Li; Haibo Zhang; Xin Zheng; Frederick A Masoudi; John A Spertus; Harlan M Krumholz; Lixin Jiang Journal: Eur Heart J Qual Care Clin Outcomes Date: 2019-01-01
Authors: Bernhard Jäger; Paul Michael Haller; Edita Piackova; Alfred Kaff; Günter Christ; Wolfgang Schreiber; Franz Weidinger; Thomas Stefenelli; Georg Delle-Karth; Gerhard Maurer; Kurt Huber Journal: Clin Res Cardiol Date: 2019-06-29 Impact factor: 5.460
Authors: Andrew Guy; Nicki Gabers; Chase Crisfield; Jennie Helmer; Shaylee C Peterson; Anders Ganstal; Caryl Harper; Ross Gibson; Sumandeep Dhesi Journal: BMJ Open Qual Date: 2021-12